InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,480.38
(
0.05%
)
US TECH 100
19,269.20
(
0.28%
)
Dow Jones
39,209.69
(
0.21%
)
Brent Oil
84.90
(
0.50%
)
Bitcoin
61,653.90
(
1.38%
)
Post# of 252400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

drbio45

Send PM Follow Ignore
Followers 36
Posts 3185
Boards Moderated 0
Alias Born 10/18/2003

drbio45

Re: mcbio post# 154054

Thursday, 12/13/2012 8:05:15 PM

Thursday, December 13, 2012 8:05:15 PM

Post# of 252400
In the trial that pfizer did against Humira, Humira had a 39 percent acr20 response

In this trial Humira's acr20 reponse was 59 percent they highest it ever reached in a clinical trial, so there was something else that was going on

The way azn and rigel are positioning the drug is that it has the best response in protecting bone loss in RA. That is a meaningful endpoint and if it succeeds that would be a meaningful claim in the market place
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up